SCHEMBL4307633

SCHEMBL4307633

Cc1ccccc1S(=O)(=O)n1ccc2c(N3CCCN(C)CC3)cccc21

nearest known ligand 0.67

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 19/20 0.67
DRD2 P14416 2/20 0.67
HTR1A P08908 1/20 0.67
HTR2A P28223 1/20 0.67
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
FABP4 P15090 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6518321 0.99 HTR6 (0.65) HTR6DRD2HTR1AHTR2ACYP3A4
SCHEMBL4318310 0.96 HTR6 (0.72) HTR6DRD2HTR1AHTR2ACYP3A4
Hydrochloric Acid SCHEMBL6522832 0.94 HTR6 (0.71) HTR6DRD2HTR1AHTR2ACYP3A4
SCHEMBL4310106 0.85 HTR6 (0.91) HTR6DRD2HTR1AHTR2ACYP3A4
Hydrochloric Acid SCHEMBL6518729 0.84 HTR6 (0.89) HTR6DRD2HTR1AHTR2ACYP3A4
SCHEMBL4305738 0.83 HTR6 (0.57) HTR6DRD2HTR1AHTR2A
SCHEMBL4313687 0.83 HTR6 (0.56) HTR6DRD2HTR1AHTR2AFABP4
SCHEMBL4313475 0.83 HTR6 (0.76) HTR6DRD2HTR1AHTR2AFABP4
Hydrochloric Acid SCHEMBL6518027 0.83 HTR6 (0.55) HTR6DRD2HTR1AHTR2AFABP4
Hydrochloric Acid SCHEMBL6523322 0.83 HTR6 (0.56) HTR6DRD2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524839-B2 Compounds, their use and preparation BIOVITRUM AM (PUBL.) 2009-04-28 US claimed
US-7524839-B2 Compounds, their use and preparation BIOVITRUM AM (PUBL.) 2009-04-28 US disclosed
US-7087750-B2 Compounds, their use and preparation BIOVITRUM AB (SE) 2006-08-08 US disclosed
US-20050256106-A1 Novel compounds, their use and preparation BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION 2005-11-17 US disclosed
EP-1326830-A1 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY BIOVITRUM AB (SE) 2003-07-16 EP disclosed
US-20020165251-A1 Novel compounds, their use and preparation PROXIMAGEN NEUROSCIENCE PLC (GB) 2002-11-07 US disclosed
WO-2002032863-A1 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY BIOVITRUM AB (SE) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165251-A1 Novel compounds, their use and preparation HTR6, HTR1A, HTR5A HTR6 1/4885DRD2 51/4885HTR1A 2/4885
US-20050256106-A1 Novel compounds, their use and preparation HTR6, HTR3C, HTR1A HTR6 1/4885DRD2 50/4885HTR1A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.